| Not Yet Recruiting | Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Cast NCT06836726 | University Health Network, Toronto | Phase 2 |
| Recruiting | A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC NCT07259213 | Radiopharm Theranostics, Ltd | Phase 1 / Phase 2 |
| Recruiting | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types NCT07503808 | IDEAYA Biosciences | Phase 1 |
| Not Yet Recruiting | Imaging of Solid Tumors Using DLL3 SPECT NCT07052760 | Thomas Hope | EARLY_Phase 1 |
| Recruiting | Study of DCC-2812 in Participants With Advanced Genitourinary Cancers NCT06966024 | Deciphera Pharmaceuticals, LLC | Phase 1 |
| Recruiting | Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC NCT06895811 | Shanghai Changzheng Hospital | Phase 1 |
| Recruiting | GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy NCT06636123 | Virginia Commonwealth University | Phase 1 |
| Withdrawn | 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer NCT06329830 | Baptist Health South Florida | Phase 1 / Phase 2 |
| Recruiting | Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy NCT05919329 | OHSU Knight Cancer Institute | Phase 4 |
| Recruiting | Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen NCT06378866 | Mayo Clinic | Phase 2 |
| Recruiting | ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical NCT06141993 | Duke University | — |
| Recruiting | Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castrat NCT06227156 | RemeGen Co., Ltd. | Phase 2 |
| Withdrawn | N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castr NCT05445882 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC NCT06228404 | Shanghai Changzheng Hospital | EARLY_Phase 1 |
| Recruiting | Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium NCT06343038 | University Hospital, Basel, Switzerland | Phase 1 |
| Unknown | Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID) NCT06251492 | Fudan University | Phase 2 |
| Recruiting | Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer NCT05534646 | Edwin Posadas, MD | Phase 2 |
| Recruiting | Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer NCT06585007 | Universitaire Ziekenhuizen KU Leuven | Phase 3 |
| Terminated | Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer NCT05501548 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Unknown | A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects NCT05607693 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Recruiting | Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer NCT05502315 | Rana McKay, MD | Phase 2 |
| Completed | Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizum NCT05585034 | Xencor, Inc. | Phase 1 |
| Terminated | Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients NCT05437679 | Angle plc | — |
| Terminated | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selec NCT05256381 | SOTIO Biotech AG | Phase 2 |
| Completed | Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastat NCT05081193 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Active Not Recruiting | Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients NCT06193993 | National University Hospital, Singapore | Phase 1 |
| Active Not Recruiting | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours NCT05057013 | Cancer Research UK | Phase 1 / Phase 2 |
| Terminated | A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combi NCT05084859 | Biosplice Therapeutics, Inc. | Phase 1 |
| Withdrawn | Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer NCT04781374 | Beth Israel Deaconess Medical Center | Phase 2 |
| Completed | HRR Prevalence in LatAm PROSPECT Study NCT04962880 | AstraZeneca | — |
| Unknown | The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC NCT04839055 | Jiangnan University | Phase 1 / Phase 2 |
| Terminated | HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) NCT03850795 | Hinova Pharmaceuticals USA, Inc. | Phase 3 |
| Completed | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors NCT04580485 | Incyte Corporation | Phase 1 |
| Completed | Polaprezinc Treatment for Enzalutamide- or Abiraterone-resistant CRPC NCT05549778 | Jiangnan University | Phase 1 / Phase 2 |
| Terminated | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors NCT04541225 | Nuvation Bio Inc. | Phase 1 |
| Recruiting | Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X) NCT04070209 | Sir Mortimer B. Davis - Jewish General Hospital | Phase 2 |
| Active Not Recruiting | Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years fo NCT04549207 | Ottawa Hospital Research Institute | Phase 4 |
| Unknown | Evaluation of Cardiotoxicity and Hypertension in Patients With Non Metastatic Castration Resistant Prostatic C NCT04567875 | Ospedale Andrea Tortora di Pagani | — |
| Unknown | Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial NCT05188911 | Fudan University | — |
| Completed | Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactiv NCT04232761 | Bayer | — |
| Recruiting | Response Evaluation of Cancer Therapeutics in Metastatic Castration-Resistant Prostate Cancer to the Bone NCT06321679 | European Institute of Oncology | — |
| Active Not Recruiting | Metastasis-directed Therapy in Castration-refractory Prostate Cancer NCT04222634 | Universitaire Ziekenhuizen KU Leuven | N/A |
| Unknown | Molecular Stratification Profiling Protocol in Metastatic Castration Resistant Prostate Cancer (mCRPC) - MAEST NCT03934164 | Institute of Cancer Research, United Kingdom | — |
| Completed | Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients NCT03569280 | Kangpu Biopharmaceuticals, Ltd. | Phase 1 |
| Unknown | A Trial of Paclitaxel (Albumin-binding) for Castration-resistant Prostate Cancer NCT04148885 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 1 / Phase 2 |
| Active Not Recruiting | pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistan NCT04090528 | University of Wisconsin, Madison | Phase 2 |
| Active Not Recruiting | Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enz NCT03700099 | Instituto do Cancer do Estado de São Paulo | Phase 2 |
| Terminated | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumo NCT04060342 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | Phase 1 |
| Completed | ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer NCT04028388 | Modra Pharmaceuticals | Phase 2 |
| Completed | A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer NCT04019327 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Completed | I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW). NCT03939689 | Progenics Pharmaceuticals, Inc. | Phase 2 |
| Completed | Safety and Pharmacokinetics of ODM-209 NCT03878823 | Orion Corporation, Orion Pharma | Phase 1 / Phase 2 |
| Terminated | A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC NCT04102124 | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
| Unknown | Liquid Biopsy-based Detection of Resistance to Targeted Therapy in Prostate Cancer Patients NCT03601143 | Technical University of Munich | — |
| Completed | Exercise for Advanced Prostate Cancer: a Multicomponent Feasibility Trial NCT03658486 | Queen's University, Belfast | N/A |
| Completed | Testosterone Therapy in Castration Resistant Prostate Cancer NCT03734653 | University of Colorado, Denver | EARLY_Phase 1 |
| Terminated | Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bo NCT03869762 | Cancer Trials Ireland | Phase 2 |
| Terminated | VAccination in Early and ADvanced Prostate caNCEr NCT03815942 | University of Oxford | Phase 1 / Phase 2 |
| Unknown | Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer NCT03506997 | Institute of Cancer Research, United Kingdom | Phase 2 |
| Terminated | A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC NCT03741712 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinet NCT03101046 | UNICANCER | Phase 2 |
| Completed | Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homolo NCT03652493 | Centre Francois Baclesse | Phase 2 |
| Completed | COMbination of Bipolar Androgen Therapy and Nivolumab NCT03554317 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Unknown | Selective Treatment According to Molecular Subtype of Prostate Cancer NCT03696186 | Tianjin Medical University Second Hospital | Phase 2 |
| Recruiting | Bipolar Androgen Therapy + Carboplatin in mCRPC NCT03522064 | St Vincent's Hospital, Sydney | Phase 2 |
| Completed | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Ma NCT03629756 | Arcus Biosciences, Inc. | Phase 1 |
| Terminated | A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Pro NCT03514836 | SOTIO a.s. | Phase 1 / Phase 2 |
| Completed | Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Se NCT03473925 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Exercise Prescription Dose for Castration Resistance Prostate Cancer Patients NCT03526562 | University Hospital, Ghent | N/A |
| Unknown | Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer NCT03960788 | University of Cincinnati | EARLY_Phase 1 |
| Completed | Prognostic Role of Free Psa Ratio at Biochemical Recurrence After Radical Treatments for Prostate Cancer NCT03927287 | Rabin Medical Center | — |
| Unknown | CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progre NCT03356912 | Consorzio Oncotech | Phase 2 |
| Unknown | Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the Prost NCT03356444 | West China Hospital | Phase 2 |
| Unknown | The Combination Therapy With Ra-223 and Enzalutamide NCT03305224 | Taro Iguchi, MD, PHD | Phase 2 |
| Active Not Recruiting | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastati NCT03170960 | Exelixis | Phase 1 |
| Completed | Bone Marrow Suppression and Recovery During Radionuclide Treatment NCT03247010 | Rigshospitalet, Denmark | — |
| Unknown | Predictive Nomogram of CRPC NCT03177551 | Tianjin Medical University Second Hospital | — |
| Completed | ModraDoc006/r in Metastatic Castration-resistant Prostate Cancer NCT03136640 | Modra Pharmaceuticals | Phase 1 |
| Completed | Home-based Exercise Intervention for Patients With Metastatic Prostate Cancer NCT03672396 | UNC Lineberger Comprehensive Cancer Center | N/A |
| Terminated | Oral Calcitriol With Ketoconazole in CRPC NCT03261336 | Donald Trump, MD | Phase 2 |
| Recruiting | Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer NCT04838899 | Sunnybrook Health Sciences Centre | N/A |
| Completed | Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer NCT02833883 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA NCT02429193 | University Health Network, Toronto | Phase 2 |
| Completed | A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study NCT02578797 | Aragon Pharmaceuticals, Inc. | Phase 1 |
| Completed | A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutam NCT02384382 | Pfizer | Phase 2 |
| Unknown | Phase 1 Study of GEN0101 in Patients With Recurrence of CRPC NCT02502994 | Norio Nonomura | Phase 1 |
| Completed | A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer NCT02346526 | Massachusetts General Hospital | Phase 2 |
| Completed | Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC) NCT02380274 | Astellas Pharma Global Development, Inc. | — |
| Unknown | CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC. NCT03381326 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | — |
| Completed | Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration NCT02346578 | Taro Iguchi, MD, PHD | Phase 2 |
| Completed | Long-Term Specified Drug Use-Results Survey for Xtandi Capsule NCT02669771 | Astellas Pharma Inc | — |
| Completed | A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cance NCT02124668 | Astellas Pharma Europe B.V. | Phase 2 |
| Completed | Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer NCT02207504 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer NCT02361086 | Innocrin Pharmaceutical | Phase 1 / Phase 2 |
| Withdrawn | Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration- NCT02054793 | Emmanuel Antonarakis, MD | Phase 1 / Phase 2 |
| Terminated | Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC NCT01995058 | Exelixis | Phase 2 |
| Completed | Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cance NCT02025010 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical F NCT02066961 | Astellas Pharma Global Development, Inc. | — |
| Terminated | F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer NCT01981707 | University Hospital, Grenoble | Phase 2 / Phase 3 |
| Terminated | Cabozantinib in Men With Castration-Resistant Prostate Cancer NCT01703065 | University of Washington | Phase 2 |
| Completed | A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer NCT01637402 | Terence Friedlander, MD | Phase 2 |
| Completed | Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR NCT01646684 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients NCT01634061 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Pr NCT01605227 | Exelixis | Phase 3 |
| Terminated | Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic C NCT01522443 | Exelixis | Phase 3 |
| Terminated | Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer NCT01981109 | Dendreon | — |
| Completed | Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer NCT01543776 | University of Chicago | Phase 2 |
| Completed | Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prost NCT01487863 | Dendreon | Phase 2 |
| Completed | A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer NCT02012920 | Innocrin Pharmaceutical | Phase 2 |
| Completed | A Trial of Triamcinolone With a GnRH Analog for Castration Resistant Prostate Cancer NCT07161778 | Barts & The London NHS Trust | Phase 2 |
| Completed | Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or P NCT01338831 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer NCT01540071 | Io Therapeutics | Phase 2 |
| Completed | OGX-427 in Castration Resistant Prostate Cancer Patients NCT01120470 | British Columbia Cancer Agency | Phase 2 |
| Completed | A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cance NCT01106352 | Bayer | Phase 1 / Phase 2 |
| Unknown | The Role of Androgen Deprivation Treatment (ADT) in Docetaxe-Prednisolone Chemotherapy for Castrate-Resistant NCT01487902 | Asan Medical Center | Phase 2 |
| Completed | Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previ NCT00974311 | Pfizer | Phase 3 |